*Sponsored
Krypton Street Announces MAIA Biotechnology (NYSE: MAIA) As Its Next Potential Breakout Idea Starting This Morning—Thursday, June 5, 2025
(MAIA) Comes Backed By Several Potential Catalysts Like…
Recent Market Recognition: (MAIA) Recently Moved Approximately 95% From $1.40 To $2.70 In Less Than A Month.
Analyst Coverage: Noble Capital Markets' Robert LeBoyer Issued A $14 Target On (MAIA) Which Suggests Over 600% Upside Potential.
Unique Scientific Approach: (MAIA) Appears To Be Advancing The Only Telomere-Targeting Agent In Clinical Trials.
Trial Expansion Planned: (MAIA) Is Preparing For A Phase 3 NSCLC Trial And Three Additional Phase 2 Studies.
Get (MAIA) On Your Radar This Morning… June 5, 2025 Dear Reader, It's not every day a company edges into territory untouched by the rest of the oncology world. But MAIA Biotechnology (NYSE: MAIA) has done just that—with a scientific approach that's both novel and fiercely ambitious. Behind this quiet momentum is a molecule now known as Ateganosine (THIO)—a telomere-targeting agent believed to be the only one of its kind currently in clinical development. That alone puts (MAIA) in rare air. But what's happening now could shift the conversation entirely. (MAIA) recently moved approximately 95% in under a month, from $1.40 on April 10, 2025, to $2.74 on May 2, 2025. But one analyst has a target on it suggesting over 600% upside potential from today's range. Robert LeBoyer, Senior Vice President and Biotechnology Equity Research Analyst at Nobile Capital Markets, currently holds a $14 target on (MAIA). 
Why (MAIA) is Topping Our Watchlist Tomorrow—Thursday, June 5, 2025
In its ongoing Phase 2 THIO-101 trial, (MAIA) reported a median overall survival of 16.9 months in NSCLC patients who had failed prior checkpoint inhibitors and chemotherapy. That figure, reported in early 2025, stands in stark contrast to the 5–6 months typically seen with standard chemotherapy. Projections currently suggest a 99% probability that Ateganosine will outperform that benchmark. This follows earlier data from the same trial suggesting up to 17.8 months median survival. Taken together, the results are pointing in one direction: durability, consistency, and broad potential in late-stage cancer care. The pipeline isn't narrow. 
(MAIA) holds three FDA Orphan Designations (for liver, lung, and brain cancers) and one Rare Pediatric Disease Designation. The latter may qualify (MAIA) for a priority review voucher if a treatment is approved—a mechanism that has historically held high value across the industry. A regulatory milestone was also reached when the United States Adopted Names (USAN) Council formally approved "Ateganosine" as the nonproprietary name for THIO—an important step in the molecule's development and visibility. What Sets the Science Apart
At the heart of (MAIA)'s approach is a dual-action immunotherapy strategy. Ateganosine targets telomeres directly—cutting off the survival mechanism of cancer cells—and then triggers a downstream immune response when followed by checkpoint inhibitors such as Libtayo® or tislelizumab. In preclinical studies, this sequence resulted in 60% complete response in lung cancer models and 100% complete response in colorectal cancer models. In both cases, animals rechallenged with large volumes of cancer cells saw no recurrence, indicating a strong immune memory effect. This science is now expanding into clinical trials across additional tumor types. A new Phase 3 trial (THIO-104) in NSCLC is expected to begin enrollment mid-2025. This pivotal trial is designed to act as either a confirmatory or full approval study depending on THIO-101's regulatory outcome. Simultaneously, three more Phase 2 trials are planned to explore Ateganosine's application in colorectal, liver, and small cell lung cancers. A Moment Behind the Scenes
In the March 2025 Letter to Shareholders, CEO Dr. Vlad Vitoc emphasized a strategy rooted in exclusivity, durability, and targeted expansion. The company's rare designations offer up to 7 years of U.S. exclusivity and 10 years in select global markets. A clinical supply agreement with global oncology leader BeiGene was also announced, supporting trials that combine Ateganosine with immune checkpoint inhibitors in challenging cancers like SCLC and HCC. Meanwhile, CSO Dr. Sergei Gryaznov, co-inventor of Ateganosine, continues to steer the scientific vision forward. His background in telomere biology and deep oncology experience helps set (MAIA) apart in a crowded space. What Comes Next
Enrollment for THIO-104 is expected to begin soon, with interim results potentially triggering a filing for early approval by 2026. Meanwhile, Part C of the expanded THIO-101 trial is now dosing new patients. (MAIA) anticipates that by the end of the year, enrollment for the colorectal, liver, and small cell lung cancer trials will also be underway. As the only company advancing a telomere-targeting anticancer agent through clinical trials, (MAIA) holds a distinctive edge—both scientifically and strategically. This Is One to Keep On Your Radar
(MAIA) may still be flying under the radar, but that doesn't tend to last long once key milestones start attracting broader attention. With a strong patent position, rare designations, and a science platform built around both tumor targeting and immune memory, this name continues to show potential worth monitoring closely. More updates to come as the next stages unfold. 7 Reasons Why (MAIA) is Topping Our Watchlist This Morning
—Thursday, June 5, 2025
1. Major Recent Move: In under a month, (MAIA) moved approximately 95%—from $1.40 on April 10 to $2.74 on May 2, 2025. 2. Analyst Eyes Target: Robert LeBoyer of Noble Capital Markets has a $14 target on (MAIA), which suggests over 600% upside potential from recent ranges. 3. Rare Development Pathway: (MAIA) is advancing what appears to be the only telomere-targeting anticancer agent currently in clinical trials. 4. Survival Data Surprise: (MAIA) reported 16.9 months median overall survival in Phase 2 NSCLC patients—far above the 5–6 month standard with chemo. 5. Multiple FDA Designations: (MAIA) holds three Orphan and one Rare Pediatric Disease Designation, offering long-term regulatory exclusivity. 6. Strong Immune Response: In preclinical studies, (MAIA)'s lead candidate triggered complete responses and immune memory in lung and colorectal models. 7. New Trials Ahead: A Phase 3 trial is expected to begin enrollment mid-2025, with three additional Phase 2 trials targeting other major cancers. Before the broader market catches on, this is one name we believe deserves a much closer look. Momentum, science, and timing are all beginning to align. And based on what we're seeing so far—this one could be early, but not for long. (MAIA) Just Landed On Our Radar—And For Good Reason…
With an approximate 95% move in under a month, a $14 analyst target suggesting significant upside from current levels, and what appears to be the only telomere-targeting anticancer agent in clinical development, MAIA Biotechnology (NYSE: MAIA) is now commanding closer attention. Add in standout survival data, multiple FDA designations, and a rapidly advancing clinical program—and it's easy to see why this one is starting to turn heads. We have all eyes on (MAIA) this morning. Take a look at (MAIA) while it's still early. Keep an eye out for my next update—it could be out at any moment Sincerely, Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter | 
